Preparation process of mesalazine sustained-release granules

CN118903043APending Publication Date: 2024-11-08ANHUI TOPSUN PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411249660.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

但该专利及现有技术制备所得的美沙拉秦缓释颗粒具有接触病变部位时间短等缺点

Benefits of technology

[0017] 1. The present invention uses modified sodium alginate and 5-aminosalicylic acid to prepare drug-containing microspheres through oil/water emulsion solvent evaporation technology, and then uses Eudragit S-100 (Eudragi S-100) to The drug-containing microspheres are wrapped to obtain mesalazine sustained-release granules. Eudragit S-100 is an anionic polymer copolymerized with methacrylic acid and methyl methacrylate, which is pH-responsive and soluble and reversible. In the acidic environment of the stomach (pH approximately 1.5-3.5), EudragitS-100 remains insoluble, thereby protecting the drug inside from premature release. When the drug reaches the end of the small intestine and colon (pH is about 5.5-7.5), Eudragit S-100 gradually dissolves, allowing the drug to be targeted and released in the colon, thus improving the colon targeting of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005031894540000081
    Figure BDA0005031894540000081
  • Figure BDA0005031894540000091
    Figure BDA0005031894540000091
  • Figure BDA0005031894540000101
    Figure BDA0005031894540000101
Patent Text Reader

Abstract

The invention relates to a preparation process of mesalazine sustained-release granules, and belongs to the technical field of pharmaceutical preparations, and the preparation process comprises the following specific operation steps: adding 5-aminosalicylic acid and modified sodium alginate into dichloromethane to obtain an organic phase; dissolving polyvinyl alcohol in water to obtain a water phase; dropwise adding the organic phase into the water phase, and stirring to obtain wet microspheres; filtering the wet microspheres, washing, and freeze-drying to obtain drug-containing microspheres; the preparation method comprises the following steps: dispersing drug-containing microspheres in an EudragS-100 solution, and then adding the EudragS-100 solution into light liquid paraffin containing Span 80 to obtain an emulsion; and dropwise adding absolute ethyl alcohol into the emulsion, stirring, filtering, washing and drying to obtain the mesalazine sustained-release granules. The preparation process of the mesalazine sustained-release granules provided by the invention has simplicity, convenience and safety, and ensures that the medicine can be released at a constant rate within a preset time range, so that continuous and effective treatment of the medicine is realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a preparation process of mesalazine sustained-release granules. Background Art

[0002] Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the intestine, which can be divided into ulcerative colitis (UC) and Crohn's disease (CD). Ulcerative colitis is the most common inflammatory disease of the rectum and colon. Its etiology and exact pathogenesis are still unclear. Typical digestive system manifestations are abdominal pain and diarrhea. Crohn's disease, also known as segmental enteritis or granulomatous enteritis, can occur in any part of the gastrointestinal tract, most commonly in the small intestine and terminal ileum. There is no fundamental cure for the disease, and it is accompanied by a variety of complications. It requires surgical treatment and has a high recurrence rate after surgery.

[0003] At present, the drug mainly used for the treatment of IBD is mesalazine (or mesalazine), chemically called 5-aminosalicylic acid (5-ASA), which mainly achieves anti-inflammatory effect by inhibiting the secretion of prostaglandins and the generation of leukotrienes and free radicals, and has a significant inhibitory effect on the inflammation of the intestinal mucosa, and has a better effect on the connective tissue of the intestinal wall with inflammation. The mesalazine preparations currently listed at home and abroad include enteric-coated tablets, sustained-release granules, sustained-release tablets, suppositories, sustained-release capsules, enema solutions, etc.

[0004] The premise of mesalazine treatment is: first, it only acts locally in the mucosa without systemic effects; second, as an effective "mucosal" therapy, it must be ensured that it is not absorbed by the proximal gastrointestinal tract. Third, the lesion mucosa and mesalazine must have a sufficiently long contact time. The patent document with patent publication number CN 116098871A discloses a preparation process of mesalazine sustained-release granules, including the following steps: mixing the main drug of mesalazine, a diluent and an anti-adhesive agent to obtain a drug-containing mixed powder; granulating the drug-containing mixed powder, polyacrylic acid resin, anti-adhesive agent and water to obtain a drug-containing soft material; extruding the drug-containing soft material using an extrusion device to obtain a drug-containing strip; spheronizing the drug-containing strip to obtain drug-containing wet granules; drying the drug-containing wet granules to obtain drug-containing dry granules; sieving the drug-containing dry granules to obtain mesalazine sustained-release granules. However, the mesalazine sustained-release granules prepared by the patent and the prior art have the disadvantages of short contact time with the lesion site. Summary of the invention

[0005] In order to solve the disadvantages of the mesalazine sustained-release granules prepared by the prior art in the background art, such as short contact time with the lesion site, the present invention provides a preparation process of the mesalazine sustained-release granules.

[0006] The purpose of the present invention can be achieved through the following technical solutions:

[0007] A preparation process of mesalazine sustained-release granules, the active ingredient of which is 5-aminosalicylic acid, comprises the following steps:

[0008] 5-aminosalicylic acid and modified sodium alginate are added to dichloromethane, stirred at 40-50°C for 2h to obtain an organic phase; emulsifier polyvinyl alcohol is dissolved in distilled water, stirred for 24h to prepare an aqueous phase; the organic phase is dripped into the aqueous phase with a syringe, stirred at 600-800rpm for 8h to emulsify, and wet microspheres are obtained; the wet microspheres are filtered and washed with distilled water for 3 times, and freeze-dried to obtain drug-containing microspheres; the drug-containing microspheres are coated with Eudragit S-100, the coated particles are collected, rinsed with anhydrous ethanol, and dried at 50°C to constant weight to obtain mesalazine sustained-release particles;

[0009] Among them, the dosage ratio of 5-aminosalicylic acid, modified sodium alginate and dichloromethane is 1g:6-9g:100mL; the dosage ratio of polyvinyl alcohol and distilled water is 2.5g:500mL; and the volume ratio of organic phase to aqueous phase is 1:5.

[0010] Furthermore, the specific operation steps of Eudragit S-100 to encapsulate the drug-containing microspheres are as follows:

[0011] The drug-containing microspheres were dispersed in Eudragit S-100 solution, and then added to light liquid paraffin containing Span 80 to obtain an emulsion; anhydrous ethanol was dropped into the emulsion, stirred at 1000 rpm for 3 hours, and then filtered to obtain coated particles.

[0012] Among them, the dosage ratio of drug-containing microspheres, Eudragit S-100 solution, and light liquid paraffin containing Span 80 is 5 mg: 2.5 mL: 40 mL; the volume ratio of emulsion to anhydrous ethanol is 40:2; the dosage ratio of Eudragit S-100 and anhydrous ethanol in Eudragit S-100 solution is 2 g: 100 mL; the volume ratio of Span 80 and light liquid paraffin in light liquid paraffin containing Span 80 is 0.4:40.

[0013] Furthermore, the preparation steps of modified sodium alginate are:

[0014] Dissolving amino-modified sodium alginate in water to obtain an amino-modified sodium alginate aqueous solution, dissolving 11-mercaptoundecanoic acid in DMF to obtain an 11-mercaptoundecanoic acid solution, adding the amino-modified sodium alginate aqueous solution to the 11-mercaptoundecanoic acid solution, stirring evenly, adding EDC and NHS, reacting at room temperature for 20-30 minutes, dialyzing, and freeze-drying to obtain modified sodium alginate;

[0015] Among them, the usage ratio of amino-modified sodium alginate and water is 4g:130mL; the usage ratio of 11-mercaptoundecanoic acid and DMF is 4-8g:130mL; the usage ratio of amino-modified sodium alginate aqueous solution, 11-mercaptoundecanoic acid solution, EDC, and NHS is 130mL:130mL:0.04-0.06g:0.04-0.06g.

[0016] Beneficial effects of the present invention:

[0017] 1. The present invention utilizes modified sodium alginate and 5-aminosalicylic acid, and the drug-containing microspheres prepared by the oil / water emulsion solvent evaporation technology, and then utilizes Eudragit S-100 (Euty S-100) to encapsulate the drug-containing microspheres to obtain mesalazine sustained-release particles. Eudragit S-100 is an anionic polymer copolymerized by methacrylic acid and methyl methacrylate, and has the soluble reversibility of pH response. In the acidic environment of the stomach (pH about 1.5-3.5), Eudragit S-100 remains insoluble, thereby protecting the internal drug from being released in advance. And when the drug reaches the end of the small intestine and the colon (pH about 5.5-7.5), Eudragit S-100 gradually dissolves, so that the drug can be targeted and released in the colon, thereby improving the colon targeting of the drug.

[0018] 2. The modified sodium alginate involved in the present invention is prepared by amide reaction of 11-mercaptoundecanoic acid and amino-modified sodium alginate, which causes thiol groups to be attached to the surface of the modified sodium alginate. These thiol groups can form disulfide bonds with the cysteine-rich part of the colonic mucus glycoprotein, thereby giving the microspheres excellent adhesion properties. In addition, the adhesion property prolongs the residence time of the sustained-release particles in the lesion site, creating favorable conditions for the sustained release of the drug. The modified sodium alginate contains a hydrophobic long-chain structure, which enhances the interaction between it and the hydrophobic drug mesalazine, making the mesalazine molecules easier to be adsorbed or embedded in the sodium alginate carrier, thereby increasing the drug loading.

[0019] 3. The preparation process of the mesalazine sustained-release granules involved in the present invention is simple and safe, and at the same time shows high production efficiency. The process optimizes the drug release kinetics of the sustained-release granules, ensuring that the drug can be released at a constant rate within a predetermined time range, thereby achieving the continuity and effectiveness of drug treatment. DETAILED DESCRIPTION

[0020] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0021] The amino-modified sodium alginate in the present invention was purchased from Xi'an Qiyue Biotechnology Co., Ltd.

[0022] Eudragit S-100 was purchased from Shanghai Dexiang Pharmaceutical Technology Co., Ltd.

[0023] Example 1

[0024] The modified sodium alginate of this embodiment is prepared by the following steps:

[0025] 4 g of amino-modified sodium alginate was dissolved in 130 mL of water to obtain an amino-modified sodium alginate aqueous solution. 4 g of 11-mercaptoundecanoic acid was dissolved in 130 mL of DMF to obtain an 11-mercaptoundecanoic acid solution. 130 mL of the amino-modified sodium alginate aqueous solution was added to 130 mL of the 11-mercaptoundecanoic acid solution, and 0.04 g of EDC and 0.04 g of NHS were added after stirring. The mixture was reacted at room temperature for 20 min, and then dialyzed and freeze-dried to obtain modified sodium alginate.

[0026] Example 2

[0027] The modified sodium alginate of this embodiment is prepared by the following steps:

[0028] 4 g of amino-modified sodium alginate was dissolved in 130 mL of water to obtain an amino-modified sodium alginate aqueous solution. 6 g of 11-mercaptoundecanoic acid was dissolved in 130 mL of DMF to obtain an 11-mercaptoundecanoic acid solution. 130 mL of the amino-modified sodium alginate aqueous solution was added to 130 mL of the 11-mercaptoundecanoic acid solution, and 0.05 g of EDC and 0.05 g of NHS were added after stirring. The mixture was reacted at room temperature for 25 min, and then dialyzed and freeze-dried to obtain modified sodium alginate.

[0029] Example 3

[0030] The modified sodium alginate of this embodiment is prepared by the following steps:

[0031] 4 g of amino-modified sodium alginate was dissolved in 130 mL of water to obtain an amino-modified sodium alginate aqueous solution, 8 g of 11-mercaptoundecanoic acid was dissolved in 130 mL of DMF to obtain an 11-mercaptoundecanoic acid solution, 130 mL of the amino-modified sodium alginate aqueous solution was added to 130 mL of the 11-mercaptoundecanoic acid solution, 0.06 g of EDC and 0.06 g of NHS were added after stirring, the mixture was reacted at room temperature for 30 min, and the modified sodium alginate was obtained by freeze-drying after dialysis.

[0032] Example 4

[0033] This embodiment provides a preparation process of mesalazine sustained-release granules, the active ingredient of which is 5-aminosalicylic acid, and the operation steps are as follows:

[0034] Add 1 g of 5-aminosalicylic acid and 6 g of modified sodium alginate to dichloromethane, stir at 40°C for 2 h to obtain an organic phase; dissolve 2.5 g of polyvinyl alcohol in 500 mL of distilled water and stir for 24 h to prepare an aqueous phase; use a syringe to drop 100 mL of the organic phase into 500 mL of the aqueous phase, stir at 600 rpm for 8 h to emulsify, and obtain wet microspheres; filter the wet microspheres, wash them three times with distilled water, and lyophilize to obtain drug-containing microspheres.

[0035] 5 mg of drug-containing microspheres were dispersed in 2.5 mL of Eudragit S-100 solution (the dosage ratio of Eudragit S-100 to anhydrous ethanol was 2 g:100 mL), and then added to 40 mL of light liquid paraffin containing Span 80 (the volume ratio of Span 80 to light liquid paraffin was 0.4:40) to obtain an emulsion; 2 mL of anhydrous ethanol was dropped into 40 mL of the emulsion, and the mixture was stirred at 1000 rpm for 3 h and then filtered to obtain coated particles; the coated particles were collected, rinsed with anhydrous ethanol, and dried at 50°C to constant weight to obtain mesalazine sustained-release particles.

[0036] The preparation process of modified sodium alginate is the same as that in Example 1.

[0037] Example 5

[0038] This embodiment provides a preparation process of mesalazine sustained-release granules, the active ingredient of which is 5-aminosalicylic acid, and the operation steps are as follows:

[0039] Add 1 g of 5-aminosalicylic acid and 8 g of modified sodium alginate to dichloromethane, stir at 45°C for 2 h to obtain an organic phase; dissolve 2.5 g of polyvinyl alcohol in 500 mL of distilled water and stir for 24 h to prepare an aqueous phase; use a syringe to drop 100 mL of the organic phase into 500 mL of the aqueous phase, stir at 700 rpm for 8 h to emulsify, and obtain wet microspheres; filter the wet microspheres, wash them three times with distilled water, and lyophilize to obtain drug-containing microspheres.

[0040] 5 mg of drug-containing microspheres were dispersed in 2.5 mL of Eudragit S-100 solution (the dosage ratio of Eudragit S-100 to anhydrous ethanol was 2 g:100 mL), and then added to 40 mL of light liquid paraffin containing Span 80 (the volume ratio of Span 80 to light liquid paraffin was 0.4:40) to obtain an emulsion; 2 mL of anhydrous ethanol was dropped into 40 mL of the emulsion, and the mixture was stirred at 1000 rpm for 3 h and then filtered to obtain coated particles; the coated particles were collected, rinsed with anhydrous ethanol, and dried at 50°C to constant weight to obtain mesalazine sustained-release particles.

[0041] The preparation process of modified sodium alginate is the same as that in Example 2.

[0042] Example 6

[0043] This embodiment provides a preparation process of mesalazine sustained-release granules, the active ingredient of which is 5-aminosalicylic acid, and the operation steps are as follows:

[0044] Add 1 g of 5-aminosalicylic acid and 9 g of modified sodium alginate to dichloromethane, stir at 50°C for 2 h to obtain an organic phase; dissolve 2.5 g of polyvinyl alcohol in 500 mL of distilled water and stir for 24 h to prepare an aqueous phase; use a syringe to drop 100 mL of the organic phase into 500 mL of the aqueous phase, stir at 800 rpm for 8 h to emulsify, and obtain wet microspheres; filter the wet microspheres, wash them three times with distilled water, and lyophilize to obtain drug-containing microspheres.

[0045] 5 mg of drug-containing microspheres were dispersed in 2.5 mL of Eudragit S-100 solution (the dosage ratio of Eudragit S-100 to anhydrous ethanol was 2 g:100 mL), and then added to 40 mL of light liquid paraffin containing Span 80 (the volume ratio of Span 80 to light liquid paraffin was 0.4:40) to obtain an emulsion; 2 mL of anhydrous ethanol was dropped into 40 mL of the emulsion, and the mixture was stirred at 1000 rpm for 3 h and then filtered to obtain coated particles; the coated particles were collected, rinsed with anhydrous ethanol, and dried at 50°C to constant weight to obtain mesalazine sustained-release particles.

[0046] The preparation process of modified sodium alginate is the same as that in Example 3.

[0047] Comparative Example 1

[0048] The remaining raw materials and steps are the same as those in Example 4, except that the modified sodium alginate in step S1 is replaced by amino-modified sodium alginate.

[0049] The mesalazine sustained-release granules prepared in Examples 4 to 6 and Comparative Example 1 were tested for performance, and the items were as follows:

[0050] 1. Adhesion test: The adhesion of the mesalazine sustained-release granules prepared in Examples 4-6 and Comparative Example 1 was tested by the eversion sac method. Male Wistar rats (230-250 g, 10 weeks old) were fasted for 24 hours and were free to drink water. After anesthesia, the duodenum and colon of the rats were removed, and then washed with normal saline to remove the contents. A 6 cm inflamed colon was obtained from TNBS-induced colitis rats, and a ligature was placed at the end of the segment to form a covered intestinal sac. The intestinal sac was placed in a test tube containing 10 mg of mesalazine sustained-release granules, 10 mL of PBS (pH 7.4) was added, and after incubation at 37 ° C with gentle stirring for 30 min, the intestinal sac was removed from PBS and centrifuged at 12000 rpm for 30 min. The mesalazine sustained-release granule precipitate was washed 3 times with deionized water and centrifuged at 12000 rpm for 30 min. After the precipitate was freeze-dried, the unbound mesalazine sustained-release particles were weighed, and the adhesion rate (%) = (initial weight of mesalazine sustained-release particles - unbound mesalazine sustained-release particles) / initial weight of mesalazine sustained-release particles × 100%. The test results are shown in Table 1.

[0051] 2. Gastrointestinal sustained-release test: Take the mesalazine sustained-release granules prepared in Examples 4 to 6 and Comparative Example 1, and adopt the dissolution method (Appendix XD of Part II of the 2010 edition of the Chinese Pharmacopoeia) according to the release determination method (Appendix XD of Part II of the 2010 edition of the Chinese Pharmacopoeia) The second method device, using pH 7.4 buffer and pH 1.5 buffer 900mL as the medium solvent, the speed is 50 revolutions per minute, operate according to the law, take 5mL of the solution for filtration at 2, 4, 6, and 8h, and replenish 5mL of the morphological solvent in the operating container in time, accurately measure 1mL of the filtrate, put it in a 10mL measuring bottle, dilute it to the scale with phosphate buffer, and test the absorbance at a wavelength of 263nm according to the UV-visible spectrophotometry (Appendix IVA of Part II of the 2010 edition of the Chinese Pharmacopoeia), and take the original preparation of KosPharmaceut i ca, USA LS Company's Nozhiping was used as the reference preparation, and the release amount of each group of products at different times was measured. The test results are shown in Table 2 and Table 3.

[0052] 3. Drug loading: 1 g of the mesalazine sustained-release granules prepared in Examples 4 to 6 and Comparative Example 2 were dispersed in 10 ml of ethanol respectively and fully expanded at 37°C for 24 hours. The expanded mesalazine sustained-release granules were crushed and centrifuged at 12000 rpm to obtain free 5-aminosalicylic acid, and the supernatant was collected and tested by HPLC. Drug loading rate (%) = amount of 5-aminosalicylic acid / amount of mesalazine sustained-release granules × 100%, and the test results are shown in Table 4.

[0053] 4. In vitro cytotoxicity: The in vitro toxicity of the mesalazine sustained-release granules prepared in Examples 4 to 6 was investigated by the MTT method, and HK-2 cells were selected as an in vitro cell model. The cells were plated in a 96-well plate at a density of 5000 cells / well and cultured in a 37°C incubator for 24 hours to allow them to adhere to the wall. The original culture medium was discarded and 100 μL of the culture medium containing mesalazine sustained-release granules was added. After further incubation for 24 hours, 100 μL of MTT solution (0.5 mg·mL -1 ), incubate for 4 hours. Discard the MTT solution, add the same volume of DMSO to dissolve the blue-purple crystals, measure the absorbance at a wavelength of 570nm and calculate the cell survival rate, cell survival rate (%) = absorbance of the drug-added group / absorbance of the blank group × 100%. The test results are shown in Table 5.

[0054] Table 1

[0055]

[0056]

[0057] It can be seen from Table 1 that the mesalazine sustained-release granules prepared in Examples 4 to 6 have better adhesion effects than those in Comparative Example 1.

[0058] Table 2

[0059] pH 1.2 buffer release

[0060] project 2h 4h 6h 8h Example 4 3.2 10.1 16.1 18.4 Example 5 2.9 9.6 15.9 18.3 Example 6 2.9 9.5 15.3 18.1 Comparative Example 1 3.3 10 16.3 18.5

[0061] It can be seen from Table 3 that the mesalazine sustained-release granules prepared in Examples 4 to 6 and Comparative Example 1 all have excellent acid resistance.

[0062] Table 3 pH 7.4 buffer release

[0063] project 2h 4h 6h 8h Example 4 22.1 42.6 66.1 98.2 Example 5 22.3 42.9 66.3 98.3 Example 6 22.4 43.2 66.4 98.6 Comparative Example 1 21.9 42.1 66.3 98.2

[0064] It can be seen from Table 3 that the mesalazine sustained-release granules prepared in Examples 4 to 6 have good release effects under alkaline conditions compared with Comparative Example 1 and have good colon targeting properties.

[0065] Table 4

[0066]

[0067]

[0068] It can be seen from Table 4 that the mesalazine sustained-release granules prepared in Examples 4 to 6 have better drug loading effects than those in Comparative Example 2.

[0069] Table 5

[0070] project Cell survival rate (%) Example 4 95.5 Example 5 95.7 Example 6 95.8 Comparative Example 1 95.4

[0071] From the data analysis of Table 5, it can be seen that the mesalazine sustained-release granules prepared in Examples 4 to 6 and Comparative Example 1 all have good biosafety.

[0072] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device.

[0073] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A preparation process of mesalazine sustained-release granules, characterized in that: The following steps are involved: 5-aminosalicylic acid and modified sodium alginate are added to dichloromethane, stirred at 40-50°C for 2 hours to obtain an organic phase; polyvinyl alcohol is dissolved in distilled water, stirred for 24 hours to prepare an aqueous phase; the organic phase is dripped into the aqueous phase, stirred for 8 hours to obtain wet microspheres; the wet microspheres are filtered, washed, and freeze-dried to obtain drug-containing microspheres; the drug-containing microspheres are coated with Eudragit S-100, the coated particles are collected, and the mesalazine sustained-release particles are obtained after rinsing and drying.

2. The preparation process of mesalazine sustained-release granules according to claim 1, characterized in that: The dosage ratio of 5-aminosalicylic acid, modified sodium alginate and dichloromethane is 1g:2-3g:100mL.

3. The preparation process of mesalazine sustained-release granules according to claim 1, characterized in that: The dosage ratio of polyvinyl alcohol to distilled water is 2.5g:500mL.

4. The preparation process of mesalazine sustained-release granules according to claim 1, characterized in that: The volume ratio of the organic phase to the aqueous phase was 1:

5.

5. The preparation process of mesalazine sustained-release granules according to claim 1, characterized in that: The specific operation of encapsulating drug-containing microspheres using Eudragit S-100 is as follows: The drug-containing microspheres were dispersed in Eudragit S-100 solution, and then added to light liquid paraffin containing Span 80 to obtain an emulsion; anhydrous ethanol was dropped into the emulsion, stirred at 1000 rpm for 3 hours, and then filtered to obtain coated particles.

6. The preparation process of mesalazine sustained-release granules according to claim 5, characterized in that: The dosage ratio of drug-containing microspheres, Eudragit S-100 solution, and light liquid paraffin containing Span 80 is 5 mg:2.5 mL:40 mL; the volume ratio of emulsion to anhydrous ethanol is 40:

2.

7. The preparation process of mesalazine sustained-release granules according to claim 5, characterized in that: The dosage ratio of Eudragit S-100 to anhydrous ethanol in the Eudragit S-100 solution is 2 g:100 mL; the volume ratio of Span 80 to light liquid paraffin in the light liquid paraffin containing Span 80 is 0.4:

40.

8. The preparation process of mesalazine sustained-release granules according to claim 1, characterized in that: The preparation steps of modified sodium alginate are: The amino-modified sodium alginate was dissolved in water to obtain an amino-modified sodium alginate aqueous solution, 11-mercaptoundecanoic acid was dissolved in DMF to obtain an 11-mercaptoundecanoic acid solution, the amino-modified sodium alginate aqueous solution was added to the 11-mercaptoundecanoic acid solution, EDC and NHS were added after stirring, the reaction was carried out at room temperature for 20-30 minutes, and the modified sodium alginate was obtained by freeze-drying after dialysis.

9. The process for preparing mesalazine sustained-release granules according to claim 8, characterized in that: The usage ratio of amino-modified sodium alginate to water is 4 g:130 mL; the usage ratio of 11-mercaptoundecanoic acid to DMF is 4-8 g:130 mL.

10. The process for preparing mesalazine sustained-release granules according to claim 8, characterized in that: The usage ratio of amino-modified sodium alginate aqueous solution, 11-mercaptoundecanoic acid solution, EDC and NHS is 130 mL: 130 mL: 0.04-0.06 g: 0.04-0.06 g.